FMD Vaccine production and research
FMD vaccine production technology was first implemented in the country at this campus. Since inception until the year 2010, IVRI, Bengaluru campus was engaged in production of FMD vaccine. During 30 years period (1980 to 2010), a total of about 175 million doses of monovalent FMD vaccine (which equals to about 52 million polyvalent vaccine) was produced and sold. Over 34 million doses of trivalent FMD vaccine were produced during 2001-02 to 2010 –11 contributing to a total revenue of more than Rs.22 crores generated through sale of FMD vaccine. The vaccine has been supplied throughout the country and was used for prevention of the disease under FMD control programme and ASCAD programme. The vaccine has contributed in reducing the incidence of FMD in the states where FMD control programme was in force.
In the vaccine production process, some of the major improvements were introduced, such as, reduction in the volume of vaccine per dose and indigenous production of aluminium hydroxide gel required for vaccine production.
A changeover from conventional gel- adjuvanted FMD vaccine to contemporary oil-adjuvanted vaccine was implemented successfully.
Evaluation of novel liposome based proprietary adjuvant, showed enhancement in the duration of immune response to FMD vaccine.
Adenovirus based new generation FMD vaccine (hAd5) in Monovalent form performed better than the trivalent Ad5-FMD vaccine at the dosage regimen followed.
Recombinant parapox-FMD viruses expressing serotypes O, A and Asia 1 capsid genes (P1-2A-3C) were generated and evaluated in cattle as trivalent and monovalent vaccine.
Providing technical backstopping to DADF, GOI, for quality testing of commercial FMD vaccine under National FMD Control Programme.
FMD diagnostic tests
Two diagnostics tests (LFD and multi-species indirect ELISA) for rapid detection of FMD and differentiating FMD infected from vaccinated animals (DIVA) were developed and released.
Recombinant virus like particles (VLPs) were evaluated as substitute for whole virus antigens in the LPBE and sandwich ELISA avoiding handling infectious materials.
AcMNP Baculovirus could replicate in Eri silkworm larvae leading to productive infection, allowing exploitation of the technology as mini bio-factory as demonstrated by the expression of foot-and-mouth disease viral protein, 3ABC.
Collaboration with international laboratories and private industries:
Due to availability of FMD vaccine research related expertise, linkages could be established with private partners (M/s.Zoetis Pharmaceutical Research Pvt Ltd) as well as International research organization (USDA and BBSRC).
The LFD and multi-species indirect ELISA technologies were transferred for commercial manufacture through the MOU signed between IVRI (ICAR) and M/s Ubio Biotechnology Systems Private Limited, Cochin on 17 July 2013.